ライフサイエンスコーパス: gentamicin

1 reams but containing neither paromomycin nor gentamicin).

2 4-oxadiazol-3-yl]benzoic acid (ataluren) and gentamicin.

3 o susceptibility to other antibiotics except gentamicin.

4 egalin and investigated its interaction with gentamicin.

5 G, amoxicillin, doxycycline, rifampicin and gentamicin.

6 became susceptible to cell death induced by gentamicin.

7 s were protected from degeneration caused by gentamicin.

8 l describing the complex between megalin and gentamicin.

9 development of synergistic combinations with gentamicin.

10 cells protected from bactericidal effects of gentamicin.

11 eloped, each validated using the nephrotoxin gentamicin.

12 infusion (BHI) agar with chloramphenicol and gentamicin.

13 rom a 12-month controlled trial of nebulized gentamicin.

14 phin protein similar to those detected using gentamicin.

15 ts predicted an increase of dystrophin after gentamicin.

16 njury induced by exposure to carbapenem A or gentamicin.

17 s, cyclosporine, cortisol, methotrexate, and gentamicin.

18 not affect the activity of ciprofloxacin and gentamicin.

19 somal decoding site and its interaction with gentamicin.

20 the in vivo nonsense suppression induced by gentamicin.

21 growth factor, fibroblast growth factor, and gentamicin.

22 eticin is much more efficacious in vivo than gentamicin.

23 ntimicrobial regimen of benzylpenicillin and gentamicin.

24 ylprednisolone reduces vertigo compared with gentamicin.

25 sponders switched from methylprednisolone to gentamicin.

26 ctors, or the presence of the aminoglycoside gentamicin.

27 uction of ROS and apoptotic cells induced by gentamicin.

28 tion of injectable procaine benzylpenicillin-gentamicin.

29 ciprofloxacin, tobramycin, tetracycline, and gentamicin.

30 ) to produce G418 during the biosynthesis of gentamicins.

31 6.56), cefpodoxime (1.91; 95%CI: 0.46-3.36), gentamicin (0.89; 95%CI: 0.06-1.84) and ciprofloxacin (0

32 Of 648 patients enrolled, 245 received gentamicin (222 of 309 [72%] in hospital A and 23 of 339

33 l gonorrhea were randomly assigned to either gentamicin 240 mg intramuscularly plus azithromycin 2 g

34 2.5%), ciprofloxacin (39.7% vs. 17.6%), and gentamicin (26.1% vs. 7.9%) (p < .001 for all comparison

35 to ciprofloxacin (59%), cefepime (35%), and gentamicin (38%).

36 oxacillin (two doses of 1 g) and single-dose gentamicin (4 mg/kg) was associated with a 94% increase

37 atympanic methylprednisolone (62.5 mg/mL) or gentamicin (40 mg/mL) injections given 2 weeks apart, an

38 significantly higher rates of resistance to gentamicin (43%), trimethoprim-sulphamethoxazole (60%),

39 ial isolates to ciprofloxacin (11.1%-24.2%), gentamicin (5.6-31.0%), tobramycin (17.2% -25.3%) and va

40 Two DMD cohorts received 14-day gentamicin (7.5mg/kg/day): Cohort 1 (n = 10) stop codon

41 0%; ciprofloxacin, 95.0%; tobramycin, 90.6%; gentamicin, 80.6%; and sulfamethoxazole/trimethoprim, 59

42 e treatment of procaine benzylpenicillin and gentamicin, 816 (751 per protocol) were allocated amoxic

43 nce interval [CI], 73 to 87) for paromomycin-gentamicin, 82% (95% CI, 74 to 87) for paromomycin alone

44 lities were the following: vancomycin, 100%; gentamicin, 88.0%; sulfamethoxazole/trimethoprim, 77.5%;

45 Overall susceptibility was highest for gentamicin (94%), which was also true of the CNS isolate

46 We implement NRS to detect gentamicin, a commonly IV-administered antibiotic and EC

47 umin was markedly reduced in the presence of gentamicin, a competitive inhibitor of megalin-dependent

48 Pharmaceutical gentamicin, a mixture of several related aminoglycosides

49 Furthermore, FM1-43 uptake and [(3)H]gentamicin accumulation were decreased in hair cells in

50 l antibiotic protocols recommended empirical gentamicin add-on therapy in only 1 of the units.

51 Both topical and intradermal gentamicin administration induced type VII collagen and

52 we determined whether topical or intradermal gentamicin administration induces type VII collagen and

53 in plus ceftriaxone (AC) and ampicillin plus gentamicin (AG) combinations for treating Enterococcus f

54 we studied the combination of L-arginine and gentamicin against planktonic persisters through time-ki

55 ant nucleases from serum samples spiked with gentamicin, allowing the convenient detection of this am

56 cells treated with the same concentration of gentamicin alone.

57 about 50% compared to topical application of gentamicin alone.

58 ated sp(3) carbon during the biosynthesis of gentamicin, an aminoglycoside antibiotic.

59 receive injectable procaine benzylpenicillin-gentamicin and 1163 infants to receive oral amoxicillin.

60 m were enrolled and randomly assigned: 30 to gentamicin and 30 to methylprednisolone.

61 e have also shown how the read-through drugs gentamicin and ataluren (PTC124) increase CLN1 (PPT1) en

62 Resistance to both gentamicin and chloramphenicol is encoded on pGNS-BAC, p

63 Addition of vancomycin, gentamicin and fluconazol into ERC contrast media was ev

64 oxicity is significantly lower than those of gentamicin and G418.

65 Compelling evidence is now available that gentamicin and Geneticin (G418) can induce the mammalian

66 Surprisingly, binding of gentamicin and kanamycin A to the chemically synthesized

67 Aminoglycoside antibiotics, such as gentamicin and kanamycin, directly target the ribosome,

68 days (group A, reference group); injectable gentamicin and oral amoxicillin for 7 days (group B); in

69 ides evidence of the efficacy of paromomycin-gentamicin and paromomycin alone for ulcerative L. major

70 owed significant readthrough with two drugs, gentamicin and paromomycin, which was confirmed by weste

71 Thus, dual treatment with gentamicin and phage resulted in lower final cell densit

72 examined the effect of 2 of these compounds, gentamicin and PTC124, in human-induced pluripotent stem

73 ples were cultured on blood agar plates with gentamicin and screened for alpha-hemolysis, optochin se

74 rature exposure on Candida growth in optisol-gentamicin and streptomycin (GS) with and without antifu

75 of all isolates had high-level resistance to gentamicin and streptomycin, respectively, including 10%

76 ncomycin (VAN); and high-level resistance to gentamicin and streptomycin.

77 rate spatial control of release of entrapped gentamicin and temporal control of release of entrapped

78 ne conditions, we studied the combination of gentamicin and the clinically compatible basic amino aci

79 We demonstrated that a combination of gentamicin and the clinically compatible basic amino aci

80 illium notatum when compared with standards, gentamicin and tioconazole for bacteria and fungi, respe

81 ve antimicrobial treatment with ticarcillin, gentamicin and vancomycin or levofloxacin eye drops lead

82 with the nonsense mutation suppressing drug gentamicin and we were able to induce expression of full

83 ) patients received ampicillin with low-dose gentamicin, and 150 (48%) patients received ampicillin m

84 per protocol) were allocated amoxicillin and gentamicin, and 817 (753 per protocol) were assigned pro

85 hose treated with procaine benzylpenicillin, gentamicin, and amoxicillin (risk difference with refere

86 ol) were assigned procaine benzylpenicillin, gentamicin, and amoxicillin.

87 have varying mechanisms of action-meropenem, gentamicin, and ceftazidime-highlighting the versatility

88 idney cyst formation, acute kidney injury by gentamicin, and crush injury in spinal cord cells.

89 cin, clarithromycin, azithromycin, rifampin, gentamicin, and doxycycline against 101 isolates of Rhod

90 e to a range of drugs, including vancomycin, gentamicin, and mupirocin.

91 2, first-line injectable agents (ampicillin, gentamicin, and penicillin) had low variable availabilit

92 complex with paromomycin, geneticin (G418), gentamicin, and TC007, solved at 3.3- to 3.7-A resolutio

93 Levofloxacin, gentamicin, and tetracycline were active against oxacill

94 baumannii-calcoaceticus complex to amikacin, gentamicin, and tobramycin using disk diffusion, Etest,

95 is associated with resistance to ampicillin, gentamicin, and trimethoprim-sulfamethoxazole and with s

96 ic resistance to ciprofloxacin, clindamycin, gentamicin, and trimethoprim-sulfamethoxazole.

97 as treated with doxycycline, rifampicin, and gentamicin, and underwent surgical repair of a penetrati

98 ed, and bacteremia resolved with daptomycin, gentamicin, and/or linezolid treatment.

99 ght for the future structure-based design of gentamicin antagonists.

100 Efficacy of gentamicin as antibiotic lock treatment (ALT) at 5 mg/mL

101 rs to be highly specific to fortimicin A and gentamicin as substrates, while the AAC(6')-Ib' domain e

102 rol), doxycycline at 40 mg/kg every 6 h, and gentamicin at 12 mg/kg every 6 h, 24 mg/kg every 12 h, a

103 Gentamicin/azithromycin and gemifloxacin/azithromycin we

104 Gentamicin/azithromycin cured 10 of 10 pharyngeal infect

105 .5%) of 202 evaluable participants receiving gentamicin/azithromycin, and 99.5% (lower 1-sided exact

106 readthrough activity but the minor component gentamicin B1 (B1) is a potent readthrough inducer.

107 Binding to megalin is highly similar to gentamicin binding to calreticulin.

108 ases flip on a timescale faster than that of gentamicin binding, supporting a stochastic gating mecha

109 Gentamicin binds to megalin with low affinity and exploi

110 lk-tryptone-glucose-glycerin and cultured on gentamicin blood agar.

111 g axis mediated hair cell protection against gentamicin by adjudin, at least in part.

112 eive a cream containing 15% paromomycin-0.5% gentamicin (called WR 279,396), 15% paromomycin alone, o

113 sue culture and in mice, we demonstrate that gentamicin can induce expression and MHC class I present

114 Large doses of gentamicin cause nephrotoxicity and ototoxicity, enterin

115 f DFO-Ga and the anti-Pseudomonas antibiotic gentamicin caused massive killing of P. aeruginosa cells

116 thin a few minutes to different antibiotics, gentamicin, ceftazidime, nitrofurantoin, nalidixic acid,

117 h in combination with low-dose, short-course gentamicin (clinical success rate, 44.2% [53/120] vs 41.

118 osed to a mixture of antibiotics (kanamycin, gentamicin, colistin, metronidazole, and vancomycin) for

119 al significant difference in SSI between the gentamicin-collagen group (16 of 329 patients [4.9%]) an

120 degradable drug carrier systems, such as the gentamicin-collagen implant, is a potential avenue for S

121 Gentamicin-collagen implants decrease the rate of SSI.

122 Gentamicin-collagen implants have been previously assess

123 vant RCTs was conducted to determine whether gentamicin-collagen implants reduce SSI.

124 Gentamicin-collagen implants significantly reduced SSI [

125 tion in 63 of 753 patients randomized to the gentamicin-collagen sponge group (8.4%) compared with 65

126 ficant differences were observed between the gentamicin-collagen sponge group and the control group,

127 Our large, multicenter trial shows that the gentamicin-collagen sponge is not effective at preventin

128 The gentamicin-collagen sponge, a surgically implantable top

129 The gentamicin-collagen sponge, an implantable topical antib

130 Single-blind randomization to insertion of 2 gentamicin-collagen sponges (total gentamicin of 260 mg)

131 sites to undergo either the insertion of two gentamicin-collagen sponges above the fascia at the time

132 oth undergoing cardiac surgery, the use of 2 gentamicin-collagen sponges compared with no interventio

133 Locally administered gentamicin-collagen sponges did not reduce the incidence

134 s as an injectable procaine benzylpenicillin-gentamicin combination for 7 days for situations in whic

135 cochlear explants, we found rapid uptake of gentamicin-conjugated Texas Red (GTTR) into hair cells f

136 Gentamicin-containing collagen sponges are widely used f

137 prophylaxis alone or with the addition of 2 gentamicin-containing collagen sponges into the hip join

138 Topical gentamicin corrected dermal-epidermal separation, improv

139 ule drug, protected cochlear hair cells from gentamicin damage.

140 In gentamicin-damaged BP, supporting cells expanded to fill

141 s confirmed that the GJIC remained robust in gentamicin-damaged explants, but regionally asymmetric c

142 pical administration of DFO-Ga together with gentamicin decreased both infiltrate and final scar size

143 as to establish the feasibility of long-term gentamicin dosing to achieve stop codon readthrough and

144 After 6 months of gentamicin, dystrophin levels significantly increased (p

145 First, we demonstrated that gentamicin enhanced readthrough activity in cells transf

146 the nephrotoxicants cisplatin, HgCl(2), and gentamicin exhibited mitochondrial toxicity prior to dec

147 xicillin for 5 days (group C); or injectable gentamicin for 2 days and oral amoxicillin for 7 days (g

148 oup B); injectable procaine benzylpenicillin-gentamicin for 2 days, then oral amoxicillin for 5 days

149 receive injectable procaine benzylpenicillin-gentamicin for 7 days (group A, reference group); inject

150 tive as injectable procaine benzylpenicillin-gentamicin for 7 days on an outpatient basis in young in

151 atients treated before January 2007 received gentamicin for a significantly longer period (28 versus

152 ndicate the therapeutic potential of topical gentamicin for NPPK.

153 efficacy at subtoxic doses limit the use of gentamicin for suppression therapy.

154 ish hospitals changed from cephalosporins to gentamicin for surgical antibiotic prophylaxis.

155 Low-dose gentamicin for the treatment of uncomplicated enterococc

156 nty exists regarding the role of synergistic gentamicin for uncomplicated Enterococcus faecalis bacte

157 ining 15% paromomycin, with and without 0.5% gentamicin, for cutaneous leishmaniasis caused by Leishm

158 ial source for endocytic protein uptake, and gentamicin further increased this concentration.

159 ne, ciprofloxacin, vancomycin, trimethoprim, gentamicin, fusidic acid, rifampin, and mupirocin) perfo

160 nd the 1,600-bp integron added resistance to gentamicin (Gen) and kanamycin (Kan).

161 atment is not feasible include intramuscular gentamicin (GEN) and oral amoxicillin.

162 To evaluate this effect, we tested gentamicin (GENT) in the inner ear following CGP deliver

163 Treatment with the bactericidal antibiotic gentamicin, given 3 h after Escherichia coli infection,

164 genes encoding resistance to kanamycin (Km), gentamicin (Gm), and zeocin (Zeo); however, wild type B.

165 ased from 19.9 (SD 16.7) to 2.5 (5.8) in the gentamicin group (87% reduction) and from 16.4 (12.5) to

166 in the injectable procaine benzylpenicillin-gentamicin group and 1145 (98%) infants in the oral amox

167 eported one adverse event each: three in the gentamicin group and three in the methylprednisolone gro

168 which was experienced by one patient in the gentamicin group and two in the methylprednisolone group

169 by a masked clinician (eight patients in the gentamicin group vs 15 in the methylprednisolone group).

170 In the procaine benzylpenicillin-gentamicin group, 234 infants (22%) failed treatment, co

171 Children receiving low-dose gentamicin had approximately twice the risk of developin

172 atients who developed AKI after prophylactic gentamicin had stage 1 AKI, but some patients developed

173 Aminoglycosides such as gentamicin have the ability to suppress translation term

174 fety and efficacy of topical and intradermal gentamicin in 5 RDEB patients with nonsense mutations.

175 There was one very major error (VME) for gentamicin in a Staphylococcus hominis isolate, six VMEs

176 n available to describe the interaction with gentamicin in atomic detail, and neither have any three-

177 However, testing of gentamicin in clinical trials has shown that safe doses

178 lism, we tested the aminoglycosides G418 and gentamicin in hepatoma cell lines (HepG2, Hep3B and Hepa

179 ontrolled compassionate use study of topical gentamicin in which five NPPK patients with c.796C>T wer

180 e reported that, by using a well-established gentamicin-induced hair cell loss model in vitro, adjudi

181 Gentamicin-induced hair cell loss was associated with a

182 m-1 was markedly upregulated in kidney after gentamicin-induced injury and had conserved phagocytic a

183 In this case, treatment with gentamicin induces a population of cells with a strong a

184 ion effects were also observed in an in vivo gentamicin-injured animal model.

185 mutated to alanine and subjected to temporal gentamicin-invasion/gentamicin-survival assay in Chinese

186 Gentamicin is a potent antibiotic that is used in combin

187 Gentamicin is an aminoglycoside widely used in treatment

188 ense-suppression (readthrough) therapy using gentamicin is applicable to NPPK.

189 Gentamicin is bactericidal, even when given on a daily s

190 The B1 content of pharmaceutical gentamicin is highly variable and major gentamicins supp

191 L-17 in high quantities after coculture with gentamicin-killed P. aeruginosa.

192 that the major components of pharmaceutical gentamicin lack PTC readthrough activity but the minor c

193 Moreover, although gentamicin local treatment alone showed poor efficacy in

194 aecalis bacteremia, the addition of low-dose gentamicin may decrease the time to bacterial clearance

195 icillin, cefazolin, ciprofloxacin, colistin, gentamicin, meropenem, and tetracycline in comparison to

196 ithin 20 min; in addition, we determined the gentamicin minimum inhibitory concentration (MIC) of the

197 nosa, piperacillin-tazobactam, cefepime, and gentamicin, Neisseria meningitidis and ceftriaxone, and

198 tion of 2 gentamicin-collagen sponges (total gentamicin of 260 mg) between the sternal halves at surg

199 xazole , multidrug), or >70% (ciprofloxacin, gentamicin) of total antimicrobial resistance.

200 The topical arm tested 0.1% gentamicin ointment or placebo application 3 times daily

201 form to evaluate the antibacterial effect of gentamicin on E. coli growth.

202 eomic techniques to establish the effects of gentamicin on the proteomes of aerobic and oxygen-limite

203 intramuscular procaine benzylpenicillin and gentamicin once a day for 2 days followed by oral amoxic

204 intramuscular procaine benzylpenicillin and gentamicin once a day for 7 days (reference); oral amoxi

205 al amoxicillin twice daily and intramuscular gentamicin once a day for 7 days; or intramuscular proca

206 The alternative regimens were intramuscular gentamicin once per day and oral amoxicillin twice per d

207 intramuscular procaine benzylpenicillin and gentamicin once per day for 2 days, then oral amoxicilli

208 intramuscular procaine benzylpenicillin and gentamicin once per day for 7 days (group A).

209 either injectable procaine benzylpenicillin-gentamicin once per day or oral amoxicillin treatment tw

210 rbapenem-sparing regimen of tigecycline plus gentamicin or colistin was effective for treating 24 of

211 ed renal clearance of inulin, resulting from gentamicin or NaCl loading, was concurrent with reduced

212 Nine were resistant to ampicillin and gentamicin or to ceftiaxone, and 13 were resistant to co

213 ) isolates were more frequently resistant to gentamicin (OR = 2.83; 95% CI = 1.23 to 6.53; P = 0.016)

214 other cationic molecules (hNP-1, vancomycin, gentamicin, or calcium-daptomycin).

215 n, vancomycin, ampicillin, sulfamethoxazole, gentamicin, or metronidazole).

216 asing microbial susceptibility was observed: gentamicin (P<0.0001), tobramycin (P = 0.005), and imipe

217 Following the withdrawal of gentamicin, PAA significantly prolonged the time interva

218 We previously demonstrated that gentamicin produced functional type VII collagen in RDEB

219 Gentamicin protection and confocal microscopy assays dem

220 Using a gentamicin protection assay and fluorescence microscopy,

221 Invasion was examined by the gentamicin protection assay and fluorescence microscopy.

222 We used a gentamicin protection assay in combination with a chloro

223 A modified gentamicin protection assay was used to investigate if H

224 A variation of the gentamicin protection assay, coupled with the detection

225 ough MDCK and DH82 cells was demonstrated by gentamicin protection assays and three-dimensional immun

226 croscopy, flow cytometry, reporter gene, and gentamicin protection assays in human epithelial cell li

227 Results obtained by utilizing modified gentamicin protection assays indicated that although the

228 invaded human erythrocytes, as shown in the gentamicin protection assays, double-immunofluorescence

229 Bacterial clearance by MDMs was assessed in gentamicin protection assays.

230 recipitation, immunoblot, reporter gene, and gentamicin protection assays.

231 d the kinetics of cell invasion, as shown by gentamicin protection assays.

232 le-immunofluorescence microscopy and ex vivo gentamicin protection of the purified erythrocyte fracti

233 ed with a wild-type strain, as judged by the gentamicin-protection assay.

234 combination of penicillin, streptomycin, and gentamicin (PSG) and then inoculated them with C. albica

235 s who received procaine benzylpenicillin and gentamicin (reference), 76 (10%) of those given amoxicil

236 successfully achieved in the mdx mouse using gentamicin, represents an important evolving treatment s

237 es of E. faecalis and 2 ME, 1 for high-level gentamicin resistance and 1 for nitrofurantoin, in E. fa

238 -1 (the first version of the vector, lacking gentamicin resistance and oriT), and recombinant clones

239 m by the targeted replacement of rquA with a gentamicin resistance cassette.

240 -resistant Enterococcus (n = 37), high-level gentamicin-resistant Enterococcus (n = 15), linezolid-re

241 ctive pressure consistently revealed a small gentamicin-resistant SCV subpopulation that emerged duri

242 With the exception of heme auxotrophs, gentamicin-resistant SCVs displayed greater catalase act

243 dent increase in the population frequency of gentamicin-resistant SCVs.

244 3 (4%) patients treated and not treated with gentamicin, respectively (P = .62).

245 ing XP-C cells, treatment with Geneticin and gentamicin resulted in (i) stabilized XPC-mRNA, which wo

246 of uningested TTSS-expressing Y. pestis with gentamicin revealed that intracellular bacteria are elim

247 ce), 76 (10%) of those given amoxicillin and gentamicin (risk difference with reference -1.9, 95% CI

248 edia, including Sabouraud dextrose agar with gentamicin (SDA), inhibitory mold agar (IMA), and brain

249 s that the recommended 2-week treatment with gentamicin seems adequate and preferable in treating non

250 od, we show evidence that the aminoglycoside gentamicin selectively affects the level of mitochondria

251 These results suggest that gentamicin should be avoided in orthopedic patients in t

252 The choice between methylprednisolone and gentamicin should be made based on clinical knowledge an

253 erkeratosis was significantly greater on the gentamicin side than the control side (P = 0.0349).

254 patients, hyperkeratosis was improved on the gentamicin side, as determined by a blinded-investigator

255 al arm tested daily intradermal injection of gentamicin solution (8 mg) or placebo into 2 intact skin

256 ned an IncI1 plasmid, encoding resistance to gentamicin, streptomycin and sulfonamides.

257 ore resistant to ciprofloxacin, clindamycin, gentamicin sulfate, and trimethoprim-sulfamethoxazole.

258 GEN is supplied as an aqueous solution of gentamicin sulphate in vials or ampoules and requires he

259 in vivo model of catheter-related infection, gentamicin supplemented with L-arginine led to complete,

260 ical gentamicin is highly variable and major gentamicins suppress the PTC readthrough activity of B1.

261 Topical and intradermal gentamicin suppresses nonsense mutations and induces typ

262 The gentamicin survival assay was used to determine the effe

263 ntifying corneal epithelial cell invasion by gentamicin survival assays, and cytotoxic activity by Tr

264 after invasion was quantified with modified gentamicin survival assays, and the role of apoptosis in

265 nd subjected to temporal gentamicin-invasion/gentamicin-survival assay in Chinese hamster ovary cells

266 For gentamicin, survivorship of mice receiving drug every 24

267 versus 74% [P = 0.02]), lower ampicillin and gentamicin susceptibilities in females aged 18 to 50 yea

268 resistant and resistant to tetracycline and gentamicin than clinical isolates.

269 In contrast, vancomycin and gentamicin, the antibiotics most commonly administered t

270 Intratympanic gentamicin, the standard treatment for refractory Menier

271 Gentamicin therapy may provide a readily available treat

272 intratympanic steroid therapy, intratympanic gentamicin therapy, and endolymphatic sac surgery.

273 ose receiving ampicillin along with low-dose gentamicin therapy.

274 cefazolin, ceftriaxone, cefepime, imipenem, gentamicin, tigecycline, doxycycline, and rifampin.

275 Because the use of gentamicin to suppress disease-causing nonsense mutation

276 Ciprofloxacin, gentamicin, tobramycin and vancomycin showed the lowest

277 Two additional stop codon DMD cohorts were gentamicin treated (7.5mg/kg) for 6 months: Cohort 3 (n

278 ion of the HLA class I peptide repertoire of gentamicin-treated cells and identified multiple peptide

279 covered from the colon, spleen, and liver of gentamicin-treated mice than of control mice.

280 teral obstruction (day 7) in mice; and after gentamicin treatment (50 or 200 mg/kg for 10 days) in ra

281 ditis were changed in January 2007, reducing gentamicin treatment in enterococcal infective endocardi

282 The longer duration of gentamicin treatment is associated with worse renal func

283 detection of borrelial transcripts following gentamicin treatment, indicated that a portion of B. bur

284 There were no untoward side effects from gentamicin treatments.

285 nalyses to determine the association between gentamicin use and the number of days alive and free of

286 Short-course empirical gentamicin use in patients with sepsis was associated wi

287 The adjusted odds ratios associated with gentamicin use were 1.39 (95% confidence interval [CI],

288 In vitro biofilm tolerance towards gentamicin was assessed using PVC 96 well-plates assays.

289 aminopenicillins, vancomycin and high level gentamicin was moderately associated with income inequal

290 SCV population expansion in the presence of gentamicin was reestablished by selection of phenotype-s

291 ited after 3 h by washing and application of gentamicin, we observed that the TER of EAEC-infected mo

292 igh MICs for moxifloxacin, levofloxacin, and gentamicin were also observed among the Helcococcus stra

293 of replicating bacteria with the antibiotic gentamicin, which inhibited NCP but not SCV replication,

294 tween HELZJ and the antibiotics amikacin and gentamicin, which resulted in decreased bacterial drug r

295 g MAR1 accumulate more of the aminoglycoside gentamicin, while mar1-1 mutant chloroplasts accumulate

296 ells, we found that the co-administration of gentamicin with PAA increased readthrough 20-40% relativ

297 udy we examined how the co-administration of gentamicin with PAA influenced the readthrough of premat

298 tro planktonic and biofilm susceptibility to gentamicin, with 99% mortality amongst clinically releva

299 Gentamicin works by flipping a conformational switch on

300 at catalyzes methylation of the 6'-carbon of gentamicin X2 (GenX2) to produce G418 during the biosynt